drugset / Trial / NCT05133752

Oral Nemonoxacin in Treating Elderly Patients With CAP

NCT05133752

Phase 4 Completed 100 enrolled TaiGen Biotechnology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study was to evaluate the safety and efficacy of oral nemonoxacin in treating elderly patients (aged ≥ 65 years) with community-acquired pneumonia (CAP).

Timeline

Start
2018-09-11
Primary completion
2020-03-23
Completion
2020-03-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Nemonoxacin Small molecule 500 mg Oral

Indications